Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial
CardioVascular and Interventional Radiology · 2026
DOI: 10.1007/s00270-026-04405-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2026. Verfasst von Takeshi Suzuki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dotter Department of Interventional Radiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA. Hauptthemen laut MEDLINE: Portasystemic Shunt, Transjugular Intrahepatic, Liver Cirrhosis, Body Composition, Hypertension, Portal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, W. L. Gore and Associates, Silver Family Foundation.
Abstract (Originalsprache)
PURPOSE: Sarcopenia and frailty are major determinants of morbidity and mortality in cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) creation for refractory ascites may reverse muscle loss, but prospective evidence is lacking. MATERIALS AND METHODS: In this single-center pilot randomized controlled trial, 26 cirrhotic adults with non-emergent complications of portal hypertension were allocated to standard of care (SOC) or SOC + TIPS creation. Fourteen completed six-month follow-up. Primary outcomes were the CT-derived skeletal (SMI) and psoas (PMI) muscle indices, adiposity, Short Physical Performance Battery, and Liver Frailty Index at baseline and at 6 months. Secondary outcomes included quality of life (QOL), MELD score, adverse events, and survival. RESULTS: In the TIPS cohort, SMI and PMI increased significantly (both p 0.05). CONCLUSION: In this pilot randomized trial, TIPS creation appeared to improve body composition, physical function, and QOL in cirrhotic patients without increasing adverse events. Larger trials are needed to confirm its effects on sarcopenia and frailty. LEVEL OF EVIDENCE: Level 1, Randomized Controlled Trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT05420753).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dotter Department of Interventional Radiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA.
- Department of Radiation Medicine, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, L337, Portland, OR, 97239, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health and Science University, 3485 S Bond Ave, OC8D, Portland, OR, USA.
- Dotter Department of Interventional Radiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA. farsad@ohsu.edu.
Förderung
- NCI NIH HHS
- W. L. Gore and Associates
- Silver Family Foundation
- National Cancer Institute
Zitieren
APA
Suzuki, T., Yamada, K., Anoushiravani, A., Pham, P., Grossberg, A. J., Naugler, W. E., & Farsad, K. (2026). Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-026-04405-7
Vancouver
Suzuki T, Yamada K, Anoushiravani A, Pham P, Grossberg AJ, Naugler WE, et al. Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial. CardioVascular and Interventional Radiology. 2026. doi:10.1007/s00270-026-04405-7
BibTeX
@article{Suzuki2026,
author = {Suzuki, Takeshi and Yamada, Kentaro and Anoushiravani, Arianna and Pham, Peter and Grossberg, Aaron J and Naugler, Willscott E and Farsad, Khashayar},
title = {Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial},
journal = {CardioVascular and Interventional Radiology},
year = {2026},
doi = {10.1007/s00270-026-04405-7}
}
EUVIMED